Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sherene Loi

Showing results (141-150 of 325) with videos related to

Pageof 33
Sort By:
Endocrine-Related Cancer|October 11, 2011
Low residual proliferation after short-term letrozole therapy is an early predictive marker of response in high proliferative ER-positive breast cancerPhilippe L Bedard, Sandeep K Singhal, Michail Ignatiadis, et al.
Breast (Edinburgh, Scotland)|February 4, 2026
Identifying premenopausal patients with early-stage hormone receptor-positive breast cancer at minimal risk of distant recurrence by breast cancer indexRuth M O'Regan, Yue Ren, Yi Zhang, et al.
Therapeutic Advances in Medical Oncology|April 29, 2025
TROPION-Breast05: a randomized phase III study of Dato-DXd with or without durvalumab versus chemotherapy plus pembrolizumab in patients with PD-L1-high locally recurrent inoperable or metastatic triple-negative breast cancerPeter Schmid, Mafalda Oliveira, Joyce O'Shaughnessy, et al.
Breast Cancer Research : BCR|April 28, 2016
Immune response in breast cancer brain metastases and their microenvironment: the role of the PD-1/PD-L axisRenata Duchnowska, Rafał Pęksa, Barbara Radecka, et al.
The Lancet. Oncology|June 21, 2011
Proposals for uniform collection of biospecimens from neoadjuvant breast cancer clinical trials: timing and specimen typesSherene Loi, W Fraser Symmans, John M S Bartlett, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 21, 2023
Differential Benefit of Metronomic Chemotherapy Among Triple-Negative Breast Cancer Subtypes Treated in the IBCSG Trial 22-00Andrea Joaquin Garcia, Mattia Rediti, David Venet, et al.
Future Oncology (London, England)|November 2, 2023
The effects of adding palbociclib to endocrine therapy to treat advanced breast cancer: a plain language summary of a study using the PALOMA-2 and PALOMA-3 trial resultsHope S Rugo, Seock-Ah Im, Anil A Joy, et al.
JAMA Oncology|April 22, 2016
Effects of Estrogen Receptor and Human Epidermal Growth Factor Receptor-2 Levels on the Efficacy of Trastuzumab: A Secondary Analysis of the HERA TrialSherene Loi, Urania Dafni, Dimitris Karlis, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 27, 2016
Serum Human Epidermal Growth Factor 2 Extracellular Domain as a Predictive Biomarker for Lapatinib Treatment Efficacy in Patients With Advanced Breast CancerChee Khoon Lee, Lucy Davies, Val J Gebski, et al.
Breast Cancer Research and Treatment|August 1, 2022
An open label, randomized phase 2 trial assessing the impact of food on the tolerability of abemaciclib in patients with advanced breast cancerElgene Lim, Frances Boyle, Meena Okera, et al.
Pageof 33

Showing results (141-150 of 325) with videos related to

Sort By:
Pageof 33
Endocrine-Related Cancer|October 11, 2011
Low residual proliferation after short-term letrozole therapy is an early predictive marker of response in high proliferative ER-positive breast cancerPhilippe L Bedard, Sandeep K Singhal, Michail Ignatiadis, et al.
Breast (Edinburgh, Scotland)|February 4, 2026
Identifying premenopausal patients with early-stage hormone receptor-positive breast cancer at minimal risk of distant recurrence by breast cancer indexRuth M O'Regan, Yue Ren, Yi Zhang, et al.
Therapeutic Advances in Medical Oncology|April 29, 2025
TROPION-Breast05: a randomized phase III study of Dato-DXd with or without durvalumab versus chemotherapy plus pembrolizumab in patients with PD-L1-high locally recurrent inoperable or metastatic triple-negative breast cancerPeter Schmid, Mafalda Oliveira, Joyce O'Shaughnessy, et al.
Breast Cancer Research : BCR|April 28, 2016
Immune response in breast cancer brain metastases and their microenvironment: the role of the PD-1/PD-L axisRenata Duchnowska, Rafał Pęksa, Barbara Radecka, et al.
The Lancet. Oncology|June 21, 2011
Proposals for uniform collection of biospecimens from neoadjuvant breast cancer clinical trials: timing and specimen typesSherene Loi, W Fraser Symmans, John M S Bartlett, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 21, 2023
Differential Benefit of Metronomic Chemotherapy Among Triple-Negative Breast Cancer Subtypes Treated in the IBCSG Trial 22-00Andrea Joaquin Garcia, Mattia Rediti, David Venet, et al.
Future Oncology (London, England)|November 2, 2023
The effects of adding palbociclib to endocrine therapy to treat advanced breast cancer: a plain language summary of a study using the PALOMA-2 and PALOMA-3 trial resultsHope S Rugo, Seock-Ah Im, Anil A Joy, et al.
JAMA Oncology|April 22, 2016
Effects of Estrogen Receptor and Human Epidermal Growth Factor Receptor-2 Levels on the Efficacy of Trastuzumab: A Secondary Analysis of the HERA TrialSherene Loi, Urania Dafni, Dimitris Karlis, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 27, 2016
Serum Human Epidermal Growth Factor 2 Extracellular Domain as a Predictive Biomarker for Lapatinib Treatment Efficacy in Patients With Advanced Breast CancerChee Khoon Lee, Lucy Davies, Val J Gebski, et al.
Breast Cancer Research and Treatment|August 1, 2022
An open label, randomized phase 2 trial assessing the impact of food on the tolerability of abemaciclib in patients with advanced breast cancerElgene Lim, Frances Boyle, Meena Okera, et al.
Pageof 33